If you’re developing world beating new therapeutics, then its crucial doctors, key opinion leaders and healthcare professionals fully understand the drug's benefits, utility and safety profile.
 
In this context, Avacta (AVCT) is currently showcasing its second major pre|CISION based treatment - a novel proteasome inhibitor (AVA3996) - at the 2023 American Association for Cancer Research annual conference in Florida. One of the world’s premiere such events.

What's more, this commitment suggests to me the company is excited about AVA3996's long-term potential, and ticking off another important milestone along the road to fully commercialising the wider pre|CISION platform.
 
The AVA3993 pre-clinical data being presented demonstrates;

1) The release of the active proteasome inhibitor (AVA2727D) from AVA3996 is specific to the enzyme FAP, which is upregulated in most solid tumours.

2) In a head to head study, AVA2727D kills cancers cells (ex-vivo) as effectively as bortezomib (Takeda's Velcade), which is one of the approved proteasome inhibitors on the estimated $2.3bn annual market by 2026.

3) In 3 different in-vivo (mouse) cancer models (melanoma, sarcoma and colorectal cancer), AVA3996 was as effective as other related chemotherapies.

4) The significant toxicities associated with bortezomib observed in these in-vivo models were not observed in the case of AVA3996. Suggesting that the exposure to the raw drug had been reduced due to the tumour targeting of the pre|CISION chemistry in AVA3996.

CEO Alastair Smith commented: "We are delighted with the progress being made in the pre-clinical development of AVA3996, the 2nd drug candidate based on our preICISIONTM platform. The potential to apply a proteasome inhibitor to the treatment of solid tumours is very exciting. And, as can be seen from our poster presented at the prestigious AACR meeting, the pre-clinical data we are generating is very encouraging in that regard. We are focused on accelerating AVA3996 through to IND filing as soon as possible, so that it can follow AVA6000 into the clinic next year."

Preliminary results are scheduled for Tuesday 25th April.